| 标题 |
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet Respiratory Medicine 作者:Martin Reck; Tony Mok; Makoto Nishio; Robert M. Jotte; Federico Cappuzzo; et al 出版日期:2019-03-26 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)